Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One research analyst...